I Paid $300 for DNA-based fitness advice and all I got was junk science
By Angela Chen,
The Verge
| 11. 20. 2017
In January of this year, I decided I would complete a half-marathon. I would push my body to the limit and be reborn as my best self. For months, I woke up at 6 to run before work, motivated by the promise of sweet endorphins and even-sweeter self-righteousness. But then the winter wore on, and I gained some weight, and now I’m back to 5Ks instead.
In my quest to return to former glory, I redownloaded the “couch to half-marathon” app and spent $100 on a pair of New Balance shoes. I became interested in a genetic-testing kit that promised to provide the information I needed to complete 13.1 miles once and for all.
Genetic testing for wellness seems like a natural choice for someone like me. I still wear my Fitbit every day two years after getting it, making me one of the few and the proud that have stuck with their device for longer than six months. I own a smart scale and a running watch; I track calories and read training forums. But the forum...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...